New Therapies
Driven by Big Data and Artificial Intelligence
Pharnext is an advanced clinical-stage biopharmaceutical company
Disease Molecular Networks
Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.
Innovative Drug Combinations
Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.
Optimal Doses
Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.
A visionary concept in drug development
PLEOTHERAPY™
Our innovative drug discovery model leverages artificial intelligence (AI) to analyze genomic big data, build disease molecular networks and identify generic compounds and/or New Chemical Entities (NCEs) that are then combined to create new effective therapies across various therapeutic areas.
Two first-in-class products in clinical development
01Charcot-Marie-Tooth Disease type 1A (CMT1A)
Explore more
PXT3003
PXT3003 is a novel synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice daily.
Explore more
02Alzheimer’s Disease
Explore more
PXT864
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice daily.
Explore more
Press releases
Pharnext annonce l’inclusion du premier patient dans l’étude PREMIER, son essai clinique pivot de Phase III dans la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)
March 31, 2021
Pharnext annonce un financement de 11 millions d’euros par le biais d’une augmentation de capital souscrite au bénéfice d’actionnaires existants et d’une émission d’obligations convertibles auprès d’investisseurs européens ; ces investisseurs européens ont indiqué une expression d’intérêt pour un montant additionnel de 25 millions d’euros en obligations convertibles
February 4, 2021
Pharnext fait le point sur son programme de développement clinique pivot dans la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)
February 1, 2021
Le Document de Référence Universel 2019 de Pharnext est approuvé par l'AMF (version anglaise uniquement)
November 10, 2020
Lettre du Dr David Horn Solomon, Directeur Général, à destination des actionnaires
October 29, 2020
Explore
Events
